FcRn blockers inhibit the transfer of IgG across the placenta during pregnancy, which may be relevant for women with MG and the risk of neonatal MG, spontaneous abortion, and arthrogryposis [57]. This evidence concerns the gene FCGRT and arthrogryposis.